Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.
Prior O, Macarro C, Navarro V, Monreal C, Ligero M, Garcia-Ruiz A, Serna G, Simonetti S, Braña I, Vieito M, Escobar M, Capdevila J, Byrne AT, Dienstmann R, Toledo R, Nuciforo P, Garralda E, Grussu F, Bernatowicz K, Perez-Lopez R. Prior O, et al. Among authors: toledo r. Radiol Artif Intell. 2024 Mar;6(2):e230118. doi: 10.1148/ryai.230118. Radiol Artif Intell. 2024. PMID: 38294307 Free PMC article.
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.
Ligero M, Serna G, El Nahhas OSM, Sansano I, Mauchanski S, Viaplana C, Calderaro J, Toledo RA, Dienstmann R, Vanguri RS, Sauter JL, Sanchez-Vega F, Shah SP, Ramón Y Cajal S, Garralda E, Nuciforo P, Perez-Lopez R, Kather JN. Ligero M, et al. Among authors: toledo ra. Cancer Res Commun. 2024 Jan 11;4(1):92-102. doi: 10.1158/2767-9764.CRC-23-0287. Cancer Res Commun. 2024. PMID: 38126740 Free PMC article.
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. Elez E, et al. Among authors: toledo ra. Nat Med. 2022 Oct;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097219 Free PMC article.
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, Otero Á, Albarran MI, Baños N, Durán Y, Bonilla V, Sarno F, Camacho-Artacho M, Sanchez-Perez T, Perea S, Álvarez R, De Martino A, Lietha D, Blanco-Aparicio C, Cubillo A, Domínguez O, Martínez-Torrecuadrada JL, Hidalgo M. Toledo RA, et al. Clin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27. Clin Cancer Res. 2018. PMID: 29588308
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Cubillo A, Álvarez-Gallego R, Muñoz M, Pond G, Perea S, Sánchez G, Martin M, Rodríguez-Pascual J, Garralda E, Vega E, de Vicente E, Quijano Y, Muñoz C, Ugidos L, Toledo RA, Hidalgo M. Cubillo A, et al. Among authors: toledo ra. Am J Clin Oncol. 2019 Jan;42(1):56-59. doi: 10.1097/COC.0000000000000474. Am J Clin Oncol. 2019. PMID: 29975196 Clinical Trial.
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M. Toledo RA, et al. Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311. Oncotarget. 2017. PMID: 27852040 Free PMC article. Clinical Trial.
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA, Hatakana R, Lourenço DM Jr, Lindsey SC, Camacho CP, Almeida M, Lima JV Jr, Sekiya T, Garralda E, Naslavsky MS, Yamamoto GL, Lazar M, Meirelles O, Sobreira TJ, Lebrao ML, Duarte YA, Blangero J, Zatz M, Cerutti JM, Maciel RM, Toledo SP. Toledo RA, et al. Among authors: toledo sp. Endocr Relat Cancer. 2015 Feb;22(1):65-76. doi: 10.1530/ERC-14-0491. Epub 2014 Nov 25. Endocr Relat Cancer. 2015. PMID: 25425582 Free PMC article.
EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease.
Vaidya A, Flores SK, Cheng ZM, Nicolas M, Deng Y, Opotowsky AR, Lourenço DM Jr, Barletta JA, Rana HQ, Pereira MA, Toledo RA, Dahia PLM. Vaidya A, et al. Among authors: toledo ra. N Engl J Med. 2018 Mar 29;378(13):1259-1261. doi: 10.1056/NEJMc1716652. N Engl J Med. 2018. PMID: 29601261 Free PMC article. No abstract available.
445 results